The Government Filed to Develop a Prescription Kratom Replacement. 30 Days Later It Moved to Schedule the Plant.
On June 1, 2026, the National Institutes of Health announced that its Investigational New Drug application for purified mitragynine had taken effect with the FDA. Thirty days later, the DEA moved to schedule 7-hydroxymitragynine and three synthetic derivatives as Schedule I controlled substances. Both actions trace back to the same federal department. This is not a coincidence. It is a sequence.
If 7-OH Is "Synthetic," Where's the Patent? The Contradiction at the Heart of the Ban
Regulators keep calling 7-OH a "synthetic opioid." But you can't patent a natural compound, and no one holds a patent on 7-OH — because it's a naturally occurring plant alkaloid. Meanwhile, pharmaceutical companies are patenting genuinely synthetic versions to sell. It can't be synthetic enough to ban and natural enough to be unpatentable. The contradiction, exposed.